View Item 

Show simple item record

Outcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort †

dc.contributor.authorKulik, L. M.en_US
dc.contributor.authorFisher, R. A.en_US
dc.contributor.authorRodrigo, D. R.en_US
dc.contributor.authorBrown, Jr., R. S.en_US
dc.contributor.authorFreise, C. E.en_US
dc.contributor.authorShaked, A.en_US
dc.contributor.authorEverhart, J. E.en_US
dc.contributor.authorEverson, G. T.en_US
dc.contributor.authorHong, J. C.en_US
dc.contributor.authorHayashi, P. H.en_US
dc.contributor.authorBerg, C. L.en_US
dc.contributor.authorLok, A. S. F.en_US
dc.date.accessioned2012-11-07T17:04:33Z
dc.date.available2014-01-07T14:51:07Zen_US
dc.date.issued2012-11en_US
dc.identifier.citationKulik, L. M.; Fisher, R. A.; Rodrigo, D. R.; Brown, Jr., R. S.; Freise, C. E.; Shaked, A.; Everhart, J. E.; Everson, G. T.; Hong, J. C.; Hayashi, P. H.; Berg, C. L.; Lok, A. S. F. (2012). "Outcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort † ." American Journal of Transplantation 12(11). <http://hdl.handle.net/2027.42/94255>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/94255
dc.publisherBlackwell Publishing Incen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherMELD Scoreen_US
dc.subject.otherHCCen_US
dc.subject.otherSurvivalen_US
dc.subject.otherRecurrenceen_US
dc.subject.otherMilan Criteriaen_US
dc.subject.otherLoco‐Regional Therapyen_US
dc.titleOutcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort †en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationumDepartment of Surgery, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherDepartment of Medicine and Surgery, Northwestern University, Chicago, ILen_US
dc.contributor.affiliationotherDepartment of Surgery, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VAen_US
dc.contributor.affiliationotherDepartment of Medicine and Surgery, Columbia University College of Physicians and Surgeons, New York, NYen_US
dc.contributor.affiliationotherDepartment of Surgery, University of California, San Francisco, San Francisco, CAen_US
dc.contributor.affiliationotherDepartment of Surgery, University of Pennsylvania, Philadelphia, PAen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Colorado, Denver, Aurora, COen_US
dc.contributor.affiliationotherNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MDen_US
dc.contributor.affiliationotherDepartment of Surgery, University of California, Los Angeles, CAen_US
dc.contributor.affiliationotherDepartment of Medicine, University of North Carolina, Chapel Hill, NCen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Virginia, Charlottesville, VAen_US
dc.identifier.pmid22994906en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/94255/1/j.1600-6143.2012.04272.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2012.04272.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceChan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: Serial alpha‐fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27: 446 – 452.en_US
dc.identifier.citedreferenceRiaz A, Ryu RK, Kulik LM, et al. Alpha‐fetoprotein response after locoregional therapy for hepatocellular carcinoma: Oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27: 5734 – 5742.en_US
dc.identifier.citedreferenceRoberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925 – 929.en_US
dc.identifier.citedreferenceCucchetti A, Cescon M, Bigonzi E, et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344 – 1354.en_US
dc.identifier.citedreferenceKulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127 ( 5 Suppl 1 ): S277 – S282.en_US
dc.identifier.citedreferenceFisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7: 1601 – 1608.en_US
dc.identifier.citedreferenceLo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007; 94: 78 – 86.en_US
dc.identifier.citedreferenceVakili K, Pomposelli JJ, Cheah YL, et al. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl 2009; 15: 1861 – 1866.en_US
dc.identifier.citedreferenceOlthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult‐to‐adult living donor liver transplant recipients: A report from the A2ALL Consortium. Ann Surg 2005; 242: 314 – 323.en_US
dc.identifier.citedreferenceAmerican Liver Tumor Study Group: A randomized prospective multi institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. Investigator Booklet and Protocol, 1998. United Network for Organ Sharing. Policy 3.6.4.4, 1998.en_US
dc.identifier.citedreferenceMazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693 – 699.en_US
dc.identifier.citedreferenceYao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatol 2001; 33: 1394 – 1403.en_US
dc.identifier.citedreferenceCarter RE, Lin Y, Lipsitz SR, Newcombe RG, Hermayer KL. Relative risk estimated from the ratio of two median unbiased estimates. J R Stat Soc Ser C Appl Stat 2010; 59: 657 – 671.en_US
dc.identifier.citedreferenceMyers, RH. Classical and Modern Regression (Bookware Companion Series). Duxbury Advanced Series in Statistics and Decision Sciences. Boston: PWS Pub. Co.; 2nd edition (August 1997 )en_US
dc.identifier.citedreferenceSandhu L, Sandroussi C, Guba M, et al. Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Comparable Survival and Recurrence. Liver Transpl 2012; 18: 315 – 322.en_US
dc.identifier.citedreferenceVitale A, D’Amico F, Frigo AC, et al. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010; 17: 2290 – 2302.en_US
dc.identifier.citedreferenceOtto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260 – 1267.en_US
dc.identifier.citedreferenceBhangui P, Vibert E, Majno P, et al. Intention‐to‐treat analysis of liver transplantation for hepatocellular carcinoma: Living versus deceased donor transplantation. Hepatol 2011; 53: 1570 – 1579.en_US
dc.identifier.citedreferenceSugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25: 310 – 312.en_US
dc.identifier.citedreferenceSoejima Y, Taketomi A, Yoshizumi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007; 83: 893 – 899.en_US
dc.identifier.citedreferenceIto T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13: 1637 – 1644.en_US
dc.identifier.citedreferenceLee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large‐volume center. Liver Transpl 2008; 14: 935 – 945.en_US
dc.identifier.citedreferenceTakada Y, Ueda M, Ito T, et al. Living donor liver transplantation as a second‐line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006; 12: 912 – 919.en_US
dc.identifier.citedreferenceTodo S, Furukawa H, Tada M. Japanese Liver Transplantation Study Group. Extending indication: Role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007; 13 ( 11 Suppl 2 ): S48 – S54.en_US
dc.identifier.citedreferenceSchaubel DE, Wolfe RA, Port FK. A sequential stratification method for estimating the effect of a time‐dependent experimental treatment in observational studies. Biometrics 2006; 62: 910 – 917.en_US
dc.identifier.citedreferenceShi JH, Huitfeldt HS, Suo ZH, Line PD. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl 2011; 17: 866 – 874.en_US
dc.identifier.citedreferenceBerg CL, Merion RM, Shearon TH, et al. Liver transplant recipient survival benefit with living donation in the MELD allocation era. Hepatol 2011; 54: 1313 – 1321.en_US
dc.identifier.citedreferenceDuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166 – 172.en_US
dc.identifier.citedreferenceCillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well‐differentiated hepatocellular carcinoma. Ann Surg 2004; 239: 150 – 159.en_US
dc.identifier.citedreferenceCillo U, Vitale A, Navaglia F, et al. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6920 – 6925.en_US
dc.identifier.citedreferenceMerani A, Majno P, Kneteman NM, et al. The impact of waiting list alpha‐fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814 – 819.en_US
dc.identifier.citedreferenceMacDonald B, Sewell JL, Harper AM, Fix OK, Roberts JP, Yao FY; American Association for the Study of Liver Disease, Boston. Pre‐transplant factors predicting tumor recurrence and mortality following liver transplantation for hepatocellular carcinoma: analysis of 1074 patients in UNOS region 5. [Abstract] Hepatol 2010; 52 ( Suppl ): 371A.en_US
dc.identifier.citedreferenceYao FY, Kerlan RK Jr., Hirose R, et al. Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: an intention‐to‐treat analysis. Hepatol 2008; 48: 819 – 27.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2012.04272.x.pdf
Size:
737.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.